Cogent Biosciences entered into a Commercial Supply Agreement with Hovione FarmaCiencia to manufacture bezuclastinib spray-dried dispersion and tablets. The company will purchase products based on rolling forecasts, committing to specified minimum percentages of its requirements that decrease over the five-year initial term, which includes automatic two-year renewals. Cogent Biosciences operates in the biotechnology industry, focusing on the development of targeted therapies for cancer.

Cogent Biosciences filed a prospectus supplement to register the offer and sale of up to $400 million in shares of common stock under an existing at-the-market offering agreement with Guggenheim Securities. This filing supplements the company's automatic shelf registration statement on Form S-3ASR, which became effective upon filing on November 7, 2025. The company has obtained a legal opinion from Gibson, Dunn & Crutcher LLP regarding the shares. Cogent Biosciences operates in the biotechnology industry, focusing on developing therapies for rare genetic diseases.

Cogent Biosciences reported second quarter 2026 financial results on August 10, 2026. The company posted a net loss of $96.4 million compared to $73.5 million in the prior year period. Research and development expenses increased to $70.8 million from $62.2 million, while general and administrative expenses rose significantly to $31.8 million from $13.4 million due to commercial readiness investments for bezuclastinib. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling $792.3 million. Including $73.6 million in gross proceeds from an at-the-market equity facility sold after quarter-end, Cogent expects its pro forma cash balance of $865.9 million to fund operations into late 2028. The filing also announced the approval of inducement equity grants for 59 new employees under Nasdaq Listing Rule 5635(c)(4). Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.